Special Issue explores molecular therapies for diabetes complications, linking metabolic dysfunction to cardiovascular and renal organ protection

Historically, diabetes management centered on lowering blood glucose. However, research increasingly links hyperglycemia, oxidative stress, and vascular damage to broader organ injury. This shift highlights the need to understand molecular processes driving complications like cardiovascular remodeling and renal dysfunction, moving beyond glycemic control to comprehensive organ protection. Current therapies, while effective for glucose, often fall short in fully preventing these diverse, long-term complications, necessitating a deeper dive into underlying molecular mechanisms.

This editorial introduces a Special Issue titled “Advances in Molecular Therapies and Disease Associations in Diabetes,” comprising five contributions. The issue's scope addresses critical areas including oxidative stress, cardiovascular remodeling, perioperative inflammation, and renal dysfunction in the context of diabetes. The collection aims to bridge therapeutic possibilities with clinically observable complications, supporting research that connects molecular interventions to meaningful patient outcomes. It reviews recent advances in diabetes pharmacology, citing examples like empagliflozin, tirzepatide, and semaglutide.

The Special Issue emphasizes the increasing connection between metabolic dysfunction and molecular processes driving organ injury across various systems. It highlights therapeutic developments that exemplify this broader perspective: EMPA-REG OUTCOME established cardiovascular benefits of empagliflozin in patients with type 2 diabetes and high cardiovascular risk. SURPASS-2 demonstrated the efficacy of dual GIP/GLP-1 receptor agonism with tirzepatide for glycemic and weight outcomes against semaglutide 1 mg. More recently, FLOW demonstrated kidney outcome benefits of semaglutide in patients with type 2 diabetes and chronic kidney disease. One contribution specifically examines diabetes-associated atrial fibrillation through the interacting effects of metabolic remodeling, inflammation, oxidative stress, fibrosis, mitochondrial dysfunction, and altered electrophysiology. This review connects these mechanisms to emerging strategies involving inflammatory pathways and atrial ion channels. The collection collectively supports attention to organ protection alongside metabolic treatment. > These examples underscore the value of molecular therapies that extend beyond glycemic control to offer significant organ-protective benefits in diabetes.